Company news
Phio Pharmaceuticals Corp. news in 2022
Phio Pharmaceuticals Corp.'s news releases, calls and decks from 2022, newest first.
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma
December 20, 2022
Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th
November 9, 2022
Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022
Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 5, 2022
Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman
September 28, 2022
Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference
September 21, 2022
Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 11, 2022
Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022
Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting
June 5, 2022
Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022
May 15, 2022
Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022
Phio Pharmaceuticals Announces Senior Leadership Personnel Change
May 4, 2022
Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022
May 2, 2022
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022
May 1, 2022
Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors
May 1, 2022
Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma
April 25, 2022
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022
April 7, 2022
Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update
March 21, 2022
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022
March 7, 2022
Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2
February 21, 2022
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma
January 10, 2022